Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant

Primary Objective

To compare the efficacy of ALVR105 to placebo in the proportion of patients with clinically significant AdV, BKV, CMV, EBV, HHV-6, and/or JCV infection and/or end-organ disease as determined by an independent, blinded Clinical Adjudication Committee (CAC) through Week 14

Study category: Cancer

Is this Study for You?

Let's Get Started!



Type of Study



University of Colorado Hospital

Principal Investigator
Jonathan Gutman,  MD

Jonathan Gutman, MD

Study ID

Protocol Number: 20-2670

More information available at NCT04693637


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers